# Semax Research: Mechanism, BDNF, Neuroprotection, and Comparative Literature > Semax mechanism of action, BDNF upregulation data, neuroprotection findings, and comparative analysis with Selank — indexed from peer-reviewed studies with inline citations. ## Semax: The Research Record Semax research spans more than thirty years, concentrated in Russian-language journals and the peer-reviewed Western publications of Russian research groups. The findings document a peptide with a multi-pathway mechanism, consistent neuroprotective results in rodent ischemia models, and an expanding application scope in 2024-2025 publications. The compound class is research peptide / unapproved compound. All dosing discussed below describes what was administered to which species by which route in published research — not recommendations for any human use. ## Semax Mechanism of Action Semax binds melanocortin receptor MC4R with a dissociation constant of approximately 2.4 ± 1.0 nM in rat basal forebrain membranes. [1] MC4R binding activates adenylyl cyclase, raising intracellular cAMP and initiating CREB phosphorylation, which drives transcription of neurotrophic genes including BDNF and NGF. [2][7] A second, parallel mechanism involves enkephalinase inhibition. Semax inhibits enkephalin-degrading serum enzymes with an IC50 of approximately 10 µM in human serum assays. [10] This prolongs the synaptic lifetime of endogenous opioid peptides without directly binding opioid receptors. A third mechanism identified in 2025 involves the mu-opioid receptor gene Oprm1 and USP18-mediated FTO deubiquitination, a pathway activated in spinal cord injury recovery models. [21] A fourth mechanism, also 2025, is Cu(II) chelation via the Met and His residues. Semax strips copper from amyloid-beta complexes, reducing ROS-induced cell death by approximately 20-23% in human neuroblastoma cells. [20] In the hippocampus specifically, Semax at 1 µM increases spontaneous intracellular calcium fluctuation frequency in CA1 pyramidal neurons — a region-specific effect not reproduced in cerebellar granule cells. [19] ## Semax and BDNF Upregulation BDNF modulation is the most replicated mechanistic finding in the Semax literature. Dolotov et al. (2006, Journal of Neurochemistry) showed that intranasal Semax at 50 and 250 µg/kg rapidly increased BDNF protein levels in rat basal forebrain within 3 hours. [1] Dolotov et al. (2006, Brain Research) reported a single intranasal dose of 50 µg/kg produced a maximal 1.4-fold increase in BDNF protein and a 3-fold increase in exon III BDNF mRNA in rat hippocampus, with a 1.6-fold increase in TrkB phosphorylation. [2] Shadrina et al. (2001) found that Semax induced an eight-fold increase in BDNF mRNA and a five-fold increase in NGF mRNA within 30 minutes in rat basal forebrain glial cell cultures. [7] Regional and temporal variation complicates a simple summary. Shadrina et al. (2010) documented region-specific and time-dependent patterns: BDNF and NGF mRNA initially decreased in hippocampus and retina at 20 minutes, then increased in frontal cortex. [8] ## Semax Neuroprotection Research In the tMCAO model, Sudarkina et al. (2021) confirmed upregulation of pCREB, downregulation of MMP-9 and c-Fos, and reduced active JNK in frontoparietal cortex at 100 µg/kg IP. [4] Medvedeva et al. (2014) performed a genome-wide transcriptional analysis of 22,226 genes in permanent MCAO rats. Over 50% of genes significantly altered at 24 hours were immune-function genes — the majority suppressed. [5] The 2025 Liu et al. study expanded neuroprotection research to spinal cord injury, showing improved Basso locomotor score and other functional recovery metrics via an Oprm1/USP18/FTO deubiquitination mechanism. [21] ## Semax vs Selank: Comparative Research Overview Both Semax (IC50 10 µM) and Selank (IC50 20 µM) inhibit enkephalin-degrading enzymes from human serum. [10] Where the profiles diverge: Semax activates dopaminergic and serotonergic pathways in the striatum. [3] Selank acts primarily on GABAergic and anxiolytic pathways. In a 6-OHDA Parkinson's disease-like rat model, Selank reduced anxiety while Semax did not significantly alter motor or passive-defensive behavior. [11] Parallel dosing produced approximately 250 overlapping differentially expressed genes, with the remainder being compound-specific. ## Cholinergic neuron survival and neurodegeneration models Grivennikov et al. (2008) reported that Semax increased in vitro survival of rat basal forebrain cholinergic neurons approximately 1.5-1.7-fold at 100 nM. [14] Choline acetyltransferase activity was stimulated in dissociated tissue cultures at the same concentration. ## Monoamine modulation and cognitive effects Intranasal Semax at 30 µg/kg produced a striatal 5-HIAA tissue content increase of approximately 25% at 2 hours, with extracellular striatal 5-HIAA gradually rising to approximately 180% within 1-4 hours. [3] ## References [1] Dolotov OV, et al. Semax binds specifically and increases BDNF in rat basal forebrain. Journal of Neurochemistry. 2006. — https://pubmed.ncbi.nlm.nih.gov/16635254/ [2] Dolotov OV, et al. Semax regulates BDNF and trkB in rat hippocampus. Brain Research. 2006. — https://pubmed.ncbi.nlm.nih.gov/16996037/ [3] Inozemtseva LS, et al. Semax activates dopaminergic and serotoninergic systems. Neuroscience Letters. 2006. — https://pubmed.ncbi.nlm.nih.gov/16362768/ [4] Sudarkina OY, et al. Protective effect of Semax in rat Cerebral Ischemia-Reperfusion. IJMS. 2021. — https://pubmed.ncbi.nlm.nih.gov/34201112/ [5] Medvedeva EV, et al. Semax affects immune and vascular gene expression in focal ischemia. BMC Genomics. 2014. — https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/ [6] Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate neurotrophin genes after cerebral ischemia. 2010. — https://pubmed.ncbi.nlm.nih.gov/19633950/ [7] Shadrina MI, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax. Neuroscience Letters. 2001. — https://pubmed.ncbi.nlm.nih.gov/11457573/ [8] Shadrina M, et al. NGF and BDNF gene expression dynamics under Semax action. J Mol Neuroscience. 2010. — https://pubmed.ncbi.nlm.nih.gov/19662538/ [9] Shevchenko KV, et al. Kinetics of Semax penetration into rat brain after intranasal administration. 2006. — https://pubmed.ncbi.nlm.nih.gov/16523722/ [10] Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes. 2001. — https://pubmed.ncbi.nlm.nih.gov/11443939/ [11] Slominsky PA, et al. Semax and selank affect behavior in 6-OHDA PD-like rats. Doklady Biological Sciences. 2017. — https://pubmed.ncbi.nlm.nih.gov/28702721/ [14] Grivennikov IA, et al. Semax effects on rat basal forebrain cholinergic neurons. Restorative Neurology and Neuroscience. 2008. — https://pubmed.ncbi.nlm.nih.gov/18431004/ [19] Volodina MA, et al. Semax effect on intracellular calcium dynamics in rat brain neurons. 2025. — https://link.springer.com/article/10.1007/s10517-025-06501-z [20] Tomasello MF, et al. Semax, a Copper Chelator Peptide, decreases Cu(II)-catalyzed ROS. 2025. — https://pmc.ncbi.nlm.nih.gov/articles/PMC12151629/ [21] Liu et al. Semax targets Oprm1 to promote deubiquitination after spinal cord injury. British Journal of Pharmacology. 2025. — https://pubmed.ncbi.nlm.nih.gov/40692165/ --- A kiln-fired digest of the peer-reviewed Semax record — heptapeptide research indexed from the literature, no clinic behind the shelf.